Table 1.
Physiological and demographic characteristics of H.E.A.L. breast cancer survivors (N = 812).
| In Situ | Localized | Regional | |
|---|---|---|---|
| Mean ± SE (n = 185) | Mean ± SE (n = 479) | Mean ± SE (n = 148) | |
| Age (years) | 55.5 ± 10.9 | 59.2 ± 12.2a | 55.4 ± 10.9b |
| Education (% H.S. graduate) | 96% | 94% | 94% |
| Weight (kg) | 71.4 ± 15.6 | 69.1 ± 14.9 | 71.4 ± 16.5 |
| Height (cm) | 163.2 ± 6.9 | 162.2 ± 7.0 | 162.3 ± 6.9 |
| BMI (wt/ht2) | 26.9 ± 5.8 | 26.3 ± 5.6 | 27.1 ± 5.9 |
| Time from Diagnosis to Interview (months) | 6.3 ± 2.3 | 6.0 ± 1.8 | 6.4 ± 1.7 |
| Race | |||
| White | 96% | 97% | 97% |
| African American | 1% | 0% | 0% |
| American Indian | 1% | 1% | 2% |
| Asian | 2% | 1% | 1% |
| Other | 0% | 1% | 0% |
| Ethnicity | |||
| Non-Hispanic White | 84% | 81% | 77% |
| Hispanic | 16% | 19% | 23% |
| Treatment | |||
| Surgery only (%) | 56% | 30% a | 14% a b |
| Radiation (%) | 44% | 48% | 11% a b |
| Chemotherapy (%) | 0% | 6% | 17% a b |
| Radiation + Chemotherapy (%) | 0% | 16% a | 58% a b |
| Tamoxifen Users (%) | 16% | 54% a | 64% a |
| Family History of Breast Cancer c | 24% | 25% | 17% |
a
significantly different from in situ (p < .05);
b
significantly different from local (p < .05);
c
First Degree Relative